Αποτελέσματα Αναζήτησης
Osteosarcoma is the most frequent primary cancer of bone (incidence: 0.2–0.3/100 000/year). The incidence is higher in adolescents (0.8–1.1/100 000/year at age 15–19), where it accounts for >10% of all solid cancers. The male : female ratio is 1.4 : 1.
Osteosarcoma is the most common primary malignancy of bone in children and young adults. This tumor has a very heterogeneous genetic profile and lacks any consistent unifying event that leads to the pathogenesis of osteosarcoma. In this review, some ...
3 Αυγ 2023 · Osteosarcoma is the most common primary bone malignancy of non-hematopoietic origin. Several subtypes of osteosarcoma have been described on pathological evaluation- conventional, small cell, periosteal, parosteal, high-grade surface, low-grade central, giant cell, and telangiectatic types.[1] Telangiectatic osteosarcoma is a rare, aggressive, high-grade malignant neoplasm, accounting for 2 to ...
Osteosarcoma is the most common primary malignant bone tumor in children and young adults. The standard-of-care curative treatment for osteosarcoma utilizes doxorubicin, cisplatin, and high-dose methotrexate, a standard that has not changed in more than 40 years.
Typical signs and symptoms are: history of pain, followed by localized swelling and limitations of joint movement and typical findings on X-rays. Definitive diagnosis requires histological examination of tumor material, which is generally obtained by open biopsy.
12 Μαρ 2021 · Osteosarcoma is the most common primary malignant bone tumor in children and young adults. The standard-of-care curative treatment for osteosarcoma utilizes doxorubicin, cisplatin, and high-dose methotrexate, a standard that has not changed in more than 40 years.
Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. ... Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol. 2009 May:20 Suppl 4:137-9. doi: 10.1093/annonc/mdp154. Authors S Bielack 1 , D Carrle, P G Casali; ESMO Guidelines Working Group. Affiliation 1 ...
